Evidence map›Paper›PMID 42453352›Full record

ArticleACS pharmacology & translational science2026

Development of Radioligand Therapy-Responsive Syngeneic Prostate Models through Murine Prostate-Specific Membrane Antigen Point Mutation.

Mathis Richard, Beatrice Louis, Marco F Taddio, Pauline Jeanjean, Clara Diaz Garcia-Prada, Abir Swaidan, Giuseppe Carlucci, Pierre-Luc Boudreault, Elie Besserer-Offroy, Christine E Mona

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mathis RichardAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Beatrice LouisAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.ORCID https://orcid.org/0000-0002-9660-9923
Marco F TaddioAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Pauline JeanjeanAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Clara Diaz Garcia-PradaAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Abir SwaidanAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Giuseppe CarlucciAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Pierre-Luc BoudreaultDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke (IPS), Université de Sherbrooke, Sherbrooke, J1H 5H3 Québec, Canada.
Elie Besserer-OffroyAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.
Christine E MonaAhmanson Translational Theranostic Division, David Geffen School of Medicine, University of California-Los Angeles, 90095 Los Angeles, California, United States.ORCID https://orcid.org/0009-0001-0776-3217

Funding

Multidimensional analyses to improve PSMA-RPT efficacy in mCRPCR01CA279094 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHANNES CZERNIN, Christine E Mona · 2023 to 2026
$2.1M
NCI NIH HHS R01 CA279094
6 · The paper itself

Abstract

Robust, reproducible, and meaningful research requires suitable murine preclinical models that effectively mimic the disease and possess a functional immune system. In the context of metastatic castration-resistant prostate cancer (mCRPC) studies and with all the opportunities offered by theranostics, particularly prostate-specific membrane antigen (PSMA)-targeted therapies, the development of PSMA-positive murine models is essential for evaluating and further exploring these therapies in immunocompetent animals. However, strategies based on the transfection of murine cell lines with the human version of PSMA have led to immune rejection by the host. To preserve an intact immune system, which is indispensable, we focused on a strategy involving the expression of the murine version of PSMA. The core objective of this strategy was to evaluate radiotracer efficacy, using imaging and therapeutic response as complementary endpoints. While the imaging results using [

Indexed as

pharmacodynamicspoint mutationprostate-specific membrane antigen (PSMA)protein−ligand interactionsradioligand therapysyngeneic prostate cancer model

Identifiers

PMID42453352
PMCPMC13366342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.